Resolution Therapeutics posts positive interim EMERALD results
Resolution Therapeutics announced positive interim six-month results from its Phase I/II EMERALD trial of RTX001 in end-stage liver disease. The analysis compared the first nine of 15 treated patients to 21 standard-of-care patients in the OPAL external control and found a 42 percent relative risk r
<p>Resolution Therapeutics announced positive interim six-month results from its Phase I/II EMERALD trial of RTX001 in end-stage liver disease. The analysis compared the first nine of 15 treated patients to 21 standard-of-care patients in the OPAL external control and found a 42 percent relative risk r</p>